News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Appoints Dr. Neil Spector to Its Scientific Advisory Board

New Member Brings Strong Oncology Expertise

BOULDER, Colo.--(BUSINESS WIRE)--April 18, 2007--Array BioPharma Inc. (NASDAQ: ARRY) today announced the appointment of Neil Spector, M.D., to its Scientific Advisory Board. Dr. Spector will focus on helping Array in the development of its cancer portfolio.

"Dr. Spector's experience, bringing two targeted anti-cancer therapies from the bench all the way to market, will be a valuable asset for Array," said Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma. "As the former Director of GlaxoSmithKline's Exploratory Medical Sciences in Oncology and the current Director of Translational Research in Oncology at Duke University Medical Center, he will contribute valuable knowledge and expertise as we move our oncology programs forward in clinical development."

"It is a great opportunity to participate in developing Array's promising drug pipeline," said Dr. Spector. "I look forward to helping to guide the development of Array's breakthrough treatments for cancer as a member of the Scientific Advisory Board."

Background - Neil Spector, M.D.

Dr. Spector, with 20 years of oncology experience, recently joined Duke University Medical Center's cancer drug development team as the new Director of Translational Research in Oncology. He also serves as Co-Director of the Experimental Therapeutics Program in the cancer center. Prior to joining Duke, Dr. Spector served as Director of GlaxoSmithKline's Exploratory Medical Sciences in Oncology, where he successfully developed two important cancer drugs, Tykerb (lapatinib) and Nelarabine (ara-G analog), from the bench to the clinic and then guided them through Food and Drug Administration (FDA) approval.

Dr. Spector received his medical degree from New Jersey Medical School, UMDNJ. He completed his internship and residency at University of Texas - Southwestern Parkland Memorial Hospital. His teaching experience also includes seven years at the Dana-Farber Cancer Institute in Boston and five years as an Assistant Professor of Medicine at the University of Miami.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life-threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2006, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of April 18, 2007. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

CONTACT: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com

SOURCE: Array BioPharma Inc.